Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
A systematic review of the infectious complications of colchicine and the use of colchicine to treat infections

Timothy McEwan, Philip C Robinson*

University of Queensland School of Clinical Medicine, Queensland, Australia

ARTICLE INFO

Objective: Colchicine has been used historically as an anti-inflammatory agent for a wide range of diseases. Little is known regarding the relationship between colchicine use and infectious disease outcomes. The objective of this study was to systematically examine infectious adverse events associated with colchicine usage and the clinical use of colchicine for infectious diseases.

Methods: A systematic review was conducted in accordance with PRISMA methodology. PubMed, EMBASE, Scopus and Cochrane Library databases were searched (up to 12th October, 2020) for interventional and observational studies that included colchicine usage associated with infectious adverse events or infectious disease outcomes.

Results: A total of 9,237 studies were initially identified and after exclusions, 36 articles comprising 21 interventional studies and 15 observational studies were included in this systematic review. There were 19 studies that reported infectious adverse events and 17 studies that examined the efficacy of colchicine in treating infectious disease. Only two out of six studies reported a significant benefit using colchicine in the management of viral liver disease. There was some evidence colchicine is beneficial in managing COVID-19 by reducing time to deterioration, length of stay in hospital and mortality. Colchicine had some benefit in managing malaria, condyloma accuminata and verruca vulgaris, viral myocarditis and erythema nodosum leprosum based on case-series or small, pilot clinical studies.

Two of the clinical trials and five of the observational studies reported significant associations between infections adverse events and colchicine usage. Risk of pneumonia was found in three studies and post-operative infections were reported in two studies. Risks of urinary tract infections, H. pylori and C. difficile were only reported by one study each.

Conclusion: There is a current lack of clinical evidence that colchicine has a role in treating or managing infectious diseases. Preliminary studies have demonstrated a possible role in the management of COVID-19 but results from more clinical trials are needed. There is inconclusive evidence that suggests colchicine is associated with increased risk of infections, particularly pneumonia.

© 2020 Elsevier Inc. All rights reserved.

Keywords: Colchicine, Infection, SARS-CoV-2, COVID-19, Infectious disease, Adverse event

A B S T R A C T

Introduction

Colchicine is a drug that has longstanding use to treat gout, Behcet’s disease and Familial Mediterranean Fever. New applications in pericarditis, liver disease, vasculitis, cardiovascular disease and dermatology have helped increase interest in colchicine [1]. There are also several clinical trials currently underway exploring the role of colchicine in combating the SARS-CoV-2 pandemic [2]. Colchicine interrupts microtubule assembly which is required for cellular processes such as maintenance of cell shape, intracellular trafficking, cell signaling, migration and division [3]. Its anti-inflammatory effects are primarily due to inhibiting neutrophil recruitment, chemotaxis, adhesion, mobilization, superoxide production and inflamasome activation [3]. Colchicine has also exhibited anti-viral properties in vitro through interruption of the tubular network required by some viruses for replication [4–6]. Despite the historic usage of colchicine little is known about the risks or benefits colchicine poses clinically in infectious disease. A meta-analysis limited to double-blinded randomized clinical trials reported that colchicine did not increase the risk of infectious adverse events [7]. However, most of these studies had small cohorts and were not powered to identify statistical differences in uncommon events such as infections. The efficacy of colchicine in managing infectious diseases has not been reviewed systematically to our knowledge. Since the therapeutic landscape for colchicine has been evolving rapidly it is worthwhile to review what is known clinically regarding

* Corresponding author.
E-mail address: philip.robinson@uq.edu.au (P.C. Robinson).
performed on 12th October 2020 and identified articles that reported infectious adverse events associated with colchicine usage or the efficacy of colchicine in managing infection.

Methods

This study was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [8]. Eligibility criteria: The PICOS framework was applied to identify studies relevant to this review.

1) Participants: Children or adults receiving colchicine for any clinical indication.
2) Intervention: Colchicine alone or in combination at therapeutic doses.
3) Comparison: Placebo, no treatment, standard treatment, alternate treatment.
4) Outcomes: Infection adverse events (number, type and severity) and/or infectious disease progression (survival, complications, microbiology and pathology).
5) Study Design: Clinical trials (randomized, non-randomised, controlled, quasi-experimental), prospective and retrospective cohort studies, case-control, cross-sectional and case series. The following studies were excluded: pre-clinical, animal studies, editorials, case reports, systematic reviews and meta-analysis.

Studies were only included if they reported either infectious adverse events and/or colchicine's effect on infectious disease progression. Infectious diseases were only relevant if there was clear infective etiology reported (e.g. idiopathic pericarditis was excluded but tuberculous pericarditis was included). Studies reporting colchicine overdose or drug-drug interactions were excluded.

Search Strategy: Electronic databases (PubMed, EMBASE, SCOPUS and Cochrane Library) were searched from inception to 12th October 2020. The initial search was performed in PubMed with the following search string: "(colchicine[MeSH Terms] OR colchicine[Text]) AND (infections[MeSH Terms] OR bacteria[Text] OR Virus[Text] OR Viral [Text] OR tuberculosis[Text] OR mycobacterium[Text] OR fungal [Text] OR "adverse effect"[Text] OR "side effect"[Text] OR "drug-related side effects and adverse reactions"[MeSH Terms]) AND (English[filter])." The other databases were searched using analogous keywords and phrases. Only papers in English were included. Bibliographical references from included studies were manually searched and included if relevant. All titles and abstracts were screened by a single reviewer to identify articles fulfilling eligibility criteria. Full-text screening was performed by a single reviewer to identify articles that reported infectious adverse events associated with colchicine usage or the efficacy of colchicine in managing infectious disease. Data was extracted from full-text studies to include participant details (age, gender) and relevant outcomes (number and severity of infectious adverse events as well as efficacy of treatment against infectious diseases). A qualitative data synthesis was performed due to the heterogeneity in study design, disease states, interventions and outcomes. The studies were categorised based on whether colchicine was used to treat infectious disease or associated with infectious adverse events.

Results

Study characteristics

Searches of PubMed, EMBASE, Scopus and Cochrane Library were performed on 12th October 2020 and identified a total of 9,237 studies after duplicates were removed. After title and abstract searching, 9,039 articles were removed leaving 198 papers. A further 162 articles were excluded after full-text screening. An overview of the study selection process and reasons for article exclusions are outlined in Figure 1. A total of 36 articles were included in this review. There were 21 interventional studies and 15 observational studies. A summary of the key characteristics and major findings of the intervention and observational studies are presented in Table 1 and Table 2, respectively. The majority of studies were randomized controlled trials (n=21), followed by retrospective cohort studies (n=6), case-series (n=5), case-control (n=2), cross-sectional (n=1) and a survey (n=1). A number of different disease states were studied including coronavirus disease 2019 (COVID-19) (n=7), viral liver disease (n=6), gout (n=4), Behcet's disease (n=2), osteoarthritis (n=2), condyloma acuminata and verrucae vulgaris (n=2), idiopathic pulmonary fibrosis (n=1), lung resection surgery (n=1), metabolic syndrome (n=1), joint arthropathy (n=1), erythema nodosum leprosum (n=1), tuberculous pericarditis (n=1), alcoholic liver cirrhosis (n=1), falciarpum malaria (n=1), myocardial infarction (n=2), post-myocardial revascularization (n=1), myocarditis (n=1) and mixed disease states (n=1). Clinical trials varied in duration (4 days to 6 years) and sample size (12 to 4745 enrolled patients). The doses of colchicine ranged from 0.5mg to 5.0mg a day with cumulative doses of 12 to 2,628mg. Observational studies ranged from 4 to 386,010 participants and the specific doses of colchicine were often not reported. The studies were categorized and analysed based on those where colchicine was used to treat infectious disease (n=17) and those that reported infectious adverse events (n=19).

Treating infectious disease

Viral liver disease

In the retrospective cohort study by Arrieta et al. [9] patients who received colchicine (1.0mg daily, 5 days a week) were significantly less likely to develop hepatocellular carcinoma at 3 years follow up compared to the non-colchicine group (9% vs 29%, respectively, p <0.05). There was a significant increase in survival in the colchicine group (252±11 months vs. 218±21 months, P<0.05). In managing hepatitis C patients, colchicine was compared to ribavirin and interferon-α [10,11]. Albillos et al. [10] found no significant change in disease related outcomes (hepatitis venous pressure gradients, hepatic vascular resistance, hemoglobin, ALTs or serum HCV-RNA) between ribavirin and colchicine (1.0mg daily, 6 months). Angelico et al. [11] reported that 23% of patients treated with interferon-α alone were HCV-RNA negative compared to only 10% of patients treated with adjunct colchicine (1.0mg daily, 6 days a week, 1.5 years) (P<0.05). Due to the poor outcome the study was terminated prematurely. Hepatitis B infections were managed with colchicine in three studies [12–14]. The study by Floreani et al. [12] found a sustained antibody response in 4 out of 6 colchicine (1.0mg daily, 5 days a week, 6 months) patients compared to 2 of the 6 control patients. Lin et al. [13] reported the cumulative incidence of cirrhosis development in the colchicine (1.0mg daily, 5 days a week, 4 years) group was 32% at 4 years compared to 73.2% in the control group (P=0.057). Episodes of acute exacerbation, defined as an acute rise in ALTs by > 300 U/L, was significantly lower in the colchicine group compared to control (32% vs 63% per patient year, P<0.05). Wang et al. [14] found the cumulative survival at 51 months was 75.9% in the colchicine (1.0mg daily, 26 months) group and 75.3% in placebo (P>0.05). Wang et al. [14] reported no significant difference in hepatitis B complications between colchicine or placebo.

COVID-19

A total of 5 studies reporting the effectiveness of colchicine in managing COVID-19 were included. A randomized controlled trial by Deferreos et al. [15] evaluated the effectiveness of colchicine (1.0mg daily, 3 weeks) on cardiac and inflammatory biomarkers and clinical outcomes in hospitalised COVID-19 patients. A total of 105 patients...
were enrolled and randomized to colchicine (n=55) and control (n=50). The primary clinical endpoint (time to clinical deterioration) occurred in 14.0% of the control group and 1.8% in the colchicine group (OR 0.11, 95% CI, 0.01-0.96, P<0.05). The primary biochemical endpoint (high-sensitivity cardiac troponins and C-reactive protein) was not statistically different between colchicine and control. Event free survival was 18.6 days in the control group and 20.7 days in the colchicine group (P<0.05). A cohort study of hospitalized COVID-19 patients by Scarsi et al.[16] compared colchicine (n=122) to standard of care (n=140). At 21 days follow up there was a lower risk of death in patients treated with colchicine compared to standard of care (HR 0.15, 95% CI, 0.06-0.37, P<0.05). A retrospective observational study by Brunetti et al. [17] compared COVID-19 patients given colchicine (1.2mg daily) to standard of care. The primary endpoint was in-hospital death within 28 days of follow up. Mortality at 28 days was 9.1% in the colchicine group compared to 33.3% in the control (OR 0.20, 95% CI, 0.05-0.80, P<0.05). Patients were also more likely to be discharged by day 28 compared to standard therapy (OR 3.0, 95% CI, 1.25-20.1, P<0.05). A case-series by Delle-Torre et al. [18] reported 9 patients with COVID-19 who were considered at high risk for progression to respiratory failure. Colchicine (1.0mg daily) was started after a median of 8 days from diagnosis and after 72 hrs of colchicine treatment all patients’ fevers were abated. A case-series of 5 patients with COVID-19 and iatrogenic allogenesis was reported by Montealegre-Gomez et al. [19]. All 5 cases received colchicine (0.5-1.0mg daily, 1-3 weeks) to manage the symptoms of iatrogenic allogenesis for up to 3 weeks prior to COVID-19 diagnosis. Despite all the cases having several co-morbidities and considered at high risk of deterioration, all 5 cases experienced only minor symptoms and did not require hospitalization.

**Tuberculous pericarditis**

A pilot study by Liebenberg et al. [20] aimed to determine the efficacy of colchicine in managing tuberculous pericarditis in South Africa. The study included 33 HIV-positive patients who all received standard TB treatment. The intervention group received colchicine (1.0mg daily, 6 weeks) as an adjunct therapy. There was no significant difference in the development of pericardial restriction between colchicine and control (RR: 1.07, CI 95%, 0.46-2.46, P>0.05).

**Malaria**

Reba et al. [21] investigated the effectiveness of a colchicine-quinine combination compared to quinine monotherapy in treating *P. falciparum* in a group of American soldiers while in Vietnam. Colchicine-quinine combination achieved cures in 77% of patients compared to 27% in quinine alone after 45 days of follow up.
Table 1
Data extraction of clinical trials included in this review (n=21).

| Reference     | Disease State     | Intervention                          | Comparator                             | Daily Dose of Colchicine (mg) | Cumulative Dose of Colchicine (mg) | Length of Intervention | Length of Follow-up | Total Sample Size   | Participant Characteristics | Outcomes                                                                 |
|---------------|-------------------|---------------------------------------|----------------------------------------|-------------------------------|-----------------------------------|------------------------|---------------------|---------------------|-----------------------------|--------------------------------------------------------------------------|
| Albillos et al. [10] | Hepatitis C     | Ribavirin, 1-1.2mg daily             | Colchicine, 0.5mg twice daily          | 1.0                           | 183                               | 6 months               | 6 months           | 42                  | (21 colchicine + 21 Ribavirin) | Not reported No significant changes in hepatic venous gradient pressure, hepatic vascular resistance, hemoglobin, ALTs or serum HCV-RNA between groups. |
| Angelico et al. [11] | Hepatitis C     | Colchicine, 1.0mg once daily + Interferon-α, 6mU subcutaneously twice weekly for 6 months then 3mU for 6 months | Interferon-α, 6mU subcutaneously twice weekly for 6 months, then 3mU for 6 months | 1.0                           | 469                               | 1.5 years              | 1.5 years           | 65                  | Mean age 48, 58% males Interferon-α + colchicine dual therapy resulted in 10% of patients being HCV-RNA negative compared to 23% in the Interferon-α monotherapy group (P<0.05). |
| Antoniou et al. [34] | Idiopathic pulmonary fibrosis | Colchicine, 1.0mg daily + prednisolone 10.0mg daily | IFN-γ 1b, 200mg subcutaneously 3 times weekly + prednisolone 10mg daily | 1.0                           | 730                               | 2 years                | 2 years            | 50                  | Mean age 67, 84% males Pneumonia was responsible for 2 deaths in both the IFN-γ 1b and colchicine groups. |
| Bessisow et al. [35] | Lung resection surgery | Colchicine, 0.6mg 4hrs before surgery, 0.6mg after surgery, 0.6mg twice daily for 9 days. | Placebo                             | 1.2                           | 12                                | 10 days                | 30 days            | 100                 | Mean age 69, 45% males Post-operative infection rates at 30-days were 12% for the colchicine group and 6% for placebo (p<0.05). |
| Das et al. [32]      | Knee osteoarthritis | Colchicine, 0.5mg twice daily + piroxicam, 20mg once daily | Placebo + piroxicam, 20mg once daily | 1.0                           | 150                               | 5 months               | 5 months           | 39                  | Mean age 53, 33% males Upper respiratory tract infections were reported in 5% of patient visits in the colchicine group compared to 1% in placebo (p<0.05). |
| Davatchi et al. [31] | Behcet’s disease | Colchicine, 1.0mg once daily         | Placebo                               | 1.0                           | 122                               | 4 months               | 4 months           | 169 (cross over study) | Mean age 32, 32% males There was 1 case of UTI and 1 case of infectious diarrhea reported in colchicine group and none in placebo. |
| Deftereos et al. [15] | COVID-19         | Colchicine, 1.5mg loading dose, 0.5mg 60mins later, 0.5mg twice daily maintenance dose for up to 3 weeks | Standard of care                      | 1.0                           | 14.0 (assuming 12-13 days in hospital) | 12-13 days (median hospital duration) | 12-13 days (median hospital duration) | 105 (55 colchicine + 50 control) | Median age 64, 58% males Primary clinical end point rate was 14.0% in control group and 1.8% in colchicine group (OR 0.11, 95% CI, 0.01-0.96, P<0.05). Event free survival was 18.6 days in control group and 20.7 days in colchicine group (P<0.05). There was no statistically significant difference in parameters such as high-sensitivity cardiac troponin and C-reactive protein. |
| Demidowich et al. [37] | Metabolic syndrome | Colchicine, 0.6mg twice daily       | Placebo                               | 1.2                           | 108                               | 3 months               | 3 months           | 40                  | Mean age 46, 23% males Upper respiratory tract infections were reported in 6.5% of patient visits in the colchicine group compared to 12.5% in the placebo (P<0.05). |

(continued on next page)
| Reference          | Disease State         | Intervention                                                                 | Comparator       | Daily Dose of Colchicine (mg) | Cumulative Dose of Colchicine (mg) | Length of Intervention | Length of Follow-up | Total Sample Size | Participant Characteristics | Outcomes                                                                 |
|--------------------|-----------------------|-------------------------------------------------------------------------------|------------------|------------------------------|-----------------------------------|------------------------|---------------------|------------------|--------------------------|---------------------------------------------------------------------------|
| Floreani et al. [12] | Hepatitis B           | Colchicine, 1.0mg once daily, 5 days a week                                    | No treatment     | 1.0                          | 130                               | 6 months               | 18 months           | 12 (6 colchicine + 6 control) | Mean age 44, 92% males       | Sustained antibody response was achieved in 4 out of 6 colchicine patients and in 2 of the 6 untreated patients. |
| Kar et al. [25]    | Erythema nodosum leprosum | Colchicine, 0.5mg three times daily                                            | Aspirin, 0.6g, three times daily | 1.5                          | 6                                 | 4 days                 | 4 days              | 68 (34 colchicine + 34 aspirin) | Mean age not reported, 80% males | Colchicine and aspirin were equally effective in managing mild reactions. For moderate reactions, 64% showed response to colchicine compared to 29% in aspirin group. For severe reactions, neither drug was useful. |
| Leung et al. [33]  | Knee osteoarthritis   | Colchicine, 0.5mg twice daily                                                   | Placebo          | 1.0                          | 112                               | 16 weeks               | 16 weeks           | 109 (54 colchicine + 55 placebo) | Mean age 31, 33% males    | Upper respiratory tract infections were reported in 31.5% of the colchicine group and 18.2% in placebo (p=0.05). There was 1 reported urinary tract infection in the placebo group with none in the colchicine group. |
| Liebenberg et al. [20] | Tuberculous pericarditis | Colchicine, 1.0mg per day                                                      | Placebo          | 1.0                          | 42                                | 6 weeks                | 16 weeks           | 33 (19 colchicine + 14 placebo) | Mean age 31, 34% males   | Risk of developing pericardial constriction was not significantly different between colchicine and control (RR 1.07; 95% CI, 0.46-2.46, p=0.05). |
| Lin et al. [13]    | Hepatitis B           | Colchicine, 1.0mg daily 5 days a week                                           | No treatment     | 1.0                          | 1043                              | 4 years                | 4 years            | 65 (38 colchicine + 27 control) | Mean age 40, 88% males    | Cumulative incidence of cirrhosis development in colchicine group was 32% at 4 years compared to 73.2% in the control group (P=0.057). The incidence of acute exacerbations was lower in the colchicine group (32% vs 63% per patient year, P=0.05). |
| Morgan et al. [38] | Alcoholic liver cirrhosis | Colchicine, 0.6mg twice daily                                                  | Placebo          | 1.2                          | 876-2628                          | 2-6 years              | 6 years            | 549 (274 colchicine + 275 placebo) | Mean age 55, 98% males | Spontaneous bacterial peritonitis was observed in 6.9% of colchicine users compared to 9.1% in the placebo group (P=0.005). |
| Nirdorf, et al. [40] | Chronic coronary disease | Colchicine, 0.5mg daily                                                        | Placebo          | 0.5                          | 435 (median 29.0 months of treatment) | 29.0 months median    | 28.6 months (mean) | 5522 (2762 colchicine + 2760 placebo) | Mean age 66, 85% males | Hospitalisation for infections occurred in 5.0% of colchicine group and 5.2% in placebo (HR 0.95, 95% CI, 0.75-1.20). Hospitalisation for pneumonia occurred in 1.7% of colchicine group and 2.0% of placebo (HR 0.84, 95% CI, 0.75-1.20). |
| Reba et al. [21]   | Falciparum malaria    | Colchicine, 0.5mg 10 times 1st day, 0.5mg twice on 2nd day + Quinine sulfate, 650mg every 8hrs for 14 days | Placebo          | 5.0mg then 1.0mg              | 6                                 | 2 days                 | 8 weeks            | 60 (22 (colchicine + 38 placebo) | Mean age 18-31, 100% males | Colchicine-quinine therapy achieved cures in 77% of patients compared to 27% in quinine alone. |
| Gout               |                       |                                                                                |                  | 0.5                          | 56                                | 16 weeks               | 24 weeks           | Mean age 69, 63% males                  |                             |                                                                            |

(continued on next page)
| Reference                          | Disease State                          | Intervention                                  | Comparator                                  | Daily Dose of Colchicine (mg) | Cumulative Dose of Colchicine (mg) | Length of Intervention | Length of Follow-up | Total Sample Size | Participant Characteristics | Outcomes                                                                                               |
|-----------------------------------|----------------------------------------|-----------------------------------------------|---------------------------------------------|---------------------------------|---------------------------------|-------------------------------|-------------------|-----------------|---------------------|----------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|
| Schlesinger et al. [29]           |                                        | Colchicine, 0.5mg daily                       | Canakinumab doses: Single dose 25mg, 50mg, 100mg, 200mg or 300mg. Four doses at four-weekly intervals (50mg, 50mg, 25mg, 25mg) | 0.5                             | 432 (108 colchicine + 324 Canakinumab) | 19.6 months (median)           | 23 months (median) | 4745 (2366 colchicine + 2379 placebo) | Mean age 61, 825 males | Infectious events were reported in 12.0% of colchicine users compared to 18.0% of total canakinumab users. No serious infectious events were reported in colchicine group compared to 6 serious infections (pneumonia, gangrene, sepsis, tonsillitis, ear infection and erysipelas) in canakinumab users. |
| Tardif et al. [41]                | Myocardial infarction                   | Colchicine, 0.5mg once daily                  | Placebo                                     | 0.5                             | 588                             | 19.6 months (median)           | 23 months (median) | 4745 (2366 colchicine + 2379 placebo) | Mean age 61, 825 males | Total Infectious events were reported in 2.2% of the colchicine group compared to 1.6% in the placebo (p > 0.05). Pneumonia was significantly more likely to occur in the colchicine group being reported in 0.9% of patients compared to 0.4% in the placebo (p > 0.05). Septic shock was reported in 0.1% of patients in both colchicine and placebo group. |
| Wang et al. [14]                  | Hepatitis B                            | Colchicine, 1.0mg once daily                  | Placebo                                     | 1.0                             | 780                             | 26 months (median)            | 15-51 months 26 months (median) | 100/50(colchicine + 50 placebo) | Mean age 60, 945 males | Cumulative survival at 51 months was 75.9% in the colchicine group and 75.3% in placebo (p > 0.05). There was no significant difference in hepatitis B complications between colchicine or placebo. |
| Yamanaka et al. [28]              | Gout                                   | Febuxostat, 10-40mg daily                     | Colchicine, 0.5mg once daily + Febuxostat, 40mg daily | 0.5                             | 42                              | 12 weeks                      | 24 weeks                      | 255 (101 febuxostat stepwise dose + 102 colchicine/Febuxostat+52 Febuxostat) | Mean age 47, 100 males | Infectious events were reported in 21.9% of patients in the stepwise febuxostat treatment group compared to 20.0% in febuxostat + colchicine and 22.0% in febuxostat 40mg. There was no significant difference between groups (p > 0.05). |
| Zarpelon et al. [42]              | Post-operative myocardial revascularisation | Colchicine, 1.0mg twice daily in pre-operative period (24 hrs before surgery), 0.5mg twice daily until discharge | Placebo                                     | 1.0                             | 14.0 (assuming 14 days in hospital) | 14 days (average length of hospital stay) | 14 days (average length of hospital stay) | 140 (71 colchicine, 69 placebo) | Mean age 61, 668 males | Patients in colchicine group were more likely to experience post-operative infections compared to control group (26.8% and 8.7%, respectively, p < 0.05). |
Table 2
Data extraction of observational studies included in this review (n=15)

| Reference                  | Disease State            | Study Design     | Study Size and Characteristics | Study Duration                  | Colchicine Exposure | Comparator       | Outcomes                                                                 |
|----------------------------|--------------------------|------------------|--------------------------------|----------------------------------|---------------------|------------------|---------------------------------------------------------------------------|
| Arrina et al. [9]           | Viral liver cirrhosis    | Retrospective    | N=186 (116 colchicine, 70 control) | Study period 1980-2000            | Colchicine, 1mg daily, 5 days a week | No colchicine     | At 3 years of follow up, development of HCC was significantly less in colchicine group compared to non-colchicine group (95% vs 29%, p < 0.05). |
| Brunetti et al. [17]        | COVID-19                 | Retrospective    | N=66 (33 colchicine, 33 control) | Study length 28 days             | 73% of patients in colchicine cohort received a loading dose of 1.2mg and maintenance dose of 0.6mg twice daily. | Standard of care  | Patients were more likely to be discharged by day 28 compared to standard therapy (OR 5.0, 95% CI, 1.25-20.1, P < 0.05). Mortality at 28 days was 9.1% in the colchicine group compared to 33.3% in the control (OR 0.20, 95% CI, 0.05-0.80, P < 0.05). |
| Delle-Torre et al. [18]     | COVID-19                 | Case-series      | N=9                             | -                                | Colchicine, 1.0mg loading dose, followed by 1.0mg daily until 3rd day of auxiliary temperature <37°C. | -                | After 72 hrs of colchicine therapy fevers in all 9 patients resolved abated and all subse quently recovered from COVID-19. |
| Gendelman et al. [43]       | COVID-19                 | Case-control     | N=14520 (1317 positive COVID-19 and 13203 negative COVID-19). Mean age 37 years, 53% males | Study period February 23rd to March 31st 2020. | Colchicine, dose unspecified, prescribed from January 1st 2020 | No colchicine     | The rate of colchicine usage was not statistically different between those who tested positive or negative for COVID-19 (0.53% vs 0.48%, p > 0.05). |
| Gigax et al. [22]           | Intraurethral condyloma acuminata | Case-series     | N=4                             | -                                | Colchicine, 10mL 0.5% intraurethral injections, 3-7 times | -                | Four cases of young men were treated successfully with colchicine.         |
| Gultekin et al. [24]        | Myocarditis              | Case-series      | N=5                             | 2 years                          | Colchicine, 0.5mg twice daily | -                | Initial ejection fractures were 21%, 18%, 25%, 20% and 21% before colchicine therapy. After 2 years ejection fractures were 59%, 45%, 40%, 25% and 41%. |
| Haslak et al. [44]          | COVID-19 and childhood auto-inflammatory disease | Web survey       | N=404 children with autoimmune diseases Mean age 11.1 years, 46% males | Study period 11th March to 15th May 2020 | Colchicine, unspecified dose | -                | There were 376 patients on colchicine treatment with only 6 of these patients contracting COVID-19. All cases recovered completely. |
| Montealegre-Gomez et al. [19]| COVID-19 and iatrogenic allogenesis | Case-series     | N=5                              | -                                | Colchicine, 0.5-1.0mg daily for 1-3 weeks prior to COVID-19 | -                | The 5 patients all had significant co-morbidities and experienced only mild symptoms of COVID-19 (headache, cough, arthralgias) without need for hospitalisation. |
| Nelson [23]                 | Verruca Vulgaris         | Case-series      | N=10                            | -                                | Colchicine, 0.1mL of 1.0mg/mL solution injected into each verrucae once a week | -                | 6 warts out of 18 in the 10 patients disappeared and did not recur after 3 months. 10 warts partially regressed but cured and 2 were unaffected. |
| Pata et al. [30]            | Behcet’s disease and H pylori infection | Cross-sectional | N=80 (40 Behcet’s disease, 40 control) | Mean colchicine therapy 1.7 years | Colchicine, dose unspecified | No colchicine | The percentage of H. pylori positive patients by histological diagnosis was 94% in patients taking colchicine but only 44% in patients not on colchicine (P < 0.05) |
| Salt et al. [36]            | Total joint arthroplasty and post-operative infections | Retrospective case-control | N=2,212 (1,106 cases, 1,106 control) | Study period 2007-2009 | Colchicine, dose unspecified, at least once 1 month before or after operation | No colchicine | The study found that 11% of cases were prescribed colchicine compared to 9% of controls in the peri-operative period (Chi^2=7.5, p < 0.05). |
| Scarsi et al. [16]          | COVID-19                 | Retrospective    | N=262 (122 colchicine, 140 control) | Study period 2007-2009 | Colchicine, 1.0mg daily + Standard of Care | Standard of Care | There was a lower risk of death in patients treated with colchicine compared to standard care (HR 0.151, 95% CI, 0.062-0.368, P < 0.05). |

(continued on next page)
| Reference          | Disease State              | Study Design     | Study Size and Characteristics | Study Duration                  | Colchicine Exposure | Comparator | Outcomes                                                                 |
|--------------------|----------------------------|------------------|--------------------------------|---------------------------------|---------------------|------------|--------------------------------------------------------------------------|
| Spaetgens et al. [27] | Gout and pneumonia/UTIs   | Retrospective cohort | N=384,328 (131,565 gout patients, 252,763 controls) Mean age 64, 74% males | Study period 1987-2014 Mean follow up 6.7 years | Colchicine, dose unspecified | No colchicine | No significant pneumonia risk in gout patients with current colchicine usage (adjusted HR, 0.88, 95% CI, 0.54-1.44). Recent exposure (>91 days) and past exposure (>91 days) were associated with increased pneumonia risk (adjusted HR, 1.60, 95% CI, 1.13-2.27) and (adjusted HR, 1.49, 95% CI, 1.32-1.68), respectively. Increased UTI risk with current and recent colchicine usage (adjusted HR 1.05, 95% CI, 1.24-1.64) and (adjusted HR: 1.29, 95% CI, 1.12-1.49), respectively. No association with pneumonia related mortality in gout patients stratified by colchicine usage. Increased risk of UTI related mortality in gout patients who never used colchicine (adjusted HR: 1.25, 95% CI, 1.04-1.49). |  
| Tsai et al. [26]   | Gout and pneumonia         | Retrospective cohort | N=24,410 (12,205 colchicine, 12,205 no colchicine) Mean age 55, 70% males | Study length 13 years | Colchicine, categorized into days of usage: <8 days, 8-32 days, ≥33 days and cumulative dosage: low (9mg), median (9-24mg) and high (≥24mg) | No colchicine | A higher incidence of pneumonia was found for colchicine users (adjusted HR, 1.42, 95% CI, 1.32-1.53). This increased risk was similar across age groups, genders and co-morbidities. Increased cumulative days of colchicine use (>33 days) and high doses (>24mg) were associated with increased pneumonia risk suggesting a dose response relationship. | 
| Young-Xu et al. [39] | Mixed autoimmune and Clostridium Difficile | Retrospective cohort | N=386,010 (77,202 colchicine, 308,808 no colchicine) Mean age 65, 99% males | Study length 2 years | Colchicine, minimum 30 day prescription, categorized as low or high dosage (≥1.2mg daily, ≥90 pills, >60 days) | No colchicine | Colchicine users were more likely to experience CDI (adjusted RR 1.44, 95% CI, 1.15-1.57). There was a dose response relationship and colchicine use was associated with increased risk of CDI recurrence (adjusted RR 1.23, 95% CI, 1.03-1.49). ICU admission or death (adjusted RR 1.44, 95% CI, 1.02-2.01). |
**Erythema nodosum leprosum**

A study by Kar et al. [25] trialed treating lepromatous leprosy with colchicine (1.5mg daily, 4 days) compared to aspirin. For mild reactions both colchicine and aspirin were equally effective. For moderate reactions, 64% showed response to colchicine compared to 29% in aspirin group. For severe reactions, neither drug was useful. Colchicine was more effective in controlling neuritis and joint pain symptoms associated with erythema nodosum leprosum compared to control.

**Infectious adverse events**

There were four studies conducted that reported infectious adverse events in gout patients using colchicine [26-29]. A retrospective study by Tsai et al. [26] compared the incidence of pneumonia in gout patients based on colchicine usage. A higher incidence of pneumonia was found for colchicine users (adjusted HR: 1.42, 95% CI, 1.32-1.53). This increased risk was similar across age groups, genders and co-morbidities. Increased cumulative days of colchicine use (>33 days) and high doses (>24mg) were associated with increased pneumonia risk suggesting a dose response relationship. The retrospective cohort study by Spaetgens et al. [27] found inconsistent infection risk associated with colchicine. There was no significant pneumonia risk in gout patients with current colchicine usage (adjusted HR, 0.88, 95% CI, 0.54-1.44). However, recent exposure (31-91days) and past exposure (>91 days) were associated with pneumonia risk (adjusted HR, 1.60, 95% CI, 1.13-2.27 and adjusted HR, 1.49, 95% CI, 1.32-1.68, respectively). Risk of urinary tract infections (UTIs) was also associated with current and recent colchicine usage (adjusted HR 1.05, 95% CI, 1.24-1.64 and adjusted HR: 1.29, 95% CI, 1.12-1.49, respectively). There was no association with pneumonia related mortality in gout patients stratified by colchicine usage. There was increased risk of UTI related mortality in gout patients who never used colchicine (adjusted HR: 1.25, 95% CI, 1.04-1.49). A randomized control trial by Schlesinger et al. [29] comparing colchicine (0.5mg daily, 16 weeks) to canakinumab for gout prophylaxis reported infectious adverse events in 13 colchicine patients (12.0%) and 58 canakinumab patients (18.0%). No serious infections were reported in the colchicine group but there were 6 serious infections (pneumonia, gangrene, sepsis, tonsillitis, ear infection and erysipelas) in 4 patients on canakinumab. The authors only attributed erysipelas as being related to canakinumab. The authors did not provide analysis regarding whether these differences were of statistical significance. A randomized controlled trial by Yamanaka et al. [28] comparing varying febuxostat doses with a febuxostat/colchicine combination found no significant differences in infectious related adverse events.

There were two studies conducted that reported infectious adverse events in patients with Behcet’s disease [30, 31]. The cross-sectional study by Pata et al. [30] reported that the prevalence of H. pylori, determined by histological diagnosis, was 94% in patients on colchicine but only 44% in patients not on colchicine (P<0.05). The mean duration of colchicine exposure was 3.7 years but doses were not reported. A cross-over trial by Davatchi et al. [31] reported 1 UTI in the colchicine group (1.0mg daily, 4 months) and 1 case of infectious diarrhea in the control group. Statistical analysis was not performed comparing the incidence of infectious events.

There were two studies of patients with osteoarthritis who received colchicine [32, 33]. The study by Das et al. [32] found no significant difference in upper respiratory tract infections after 5 months between colchicine (1.0mg daily, 5 months) and control (5% vs 1% of patient visits, respectively, P>0.05). Similarly, Leung et al. [33] reported no significant difference in upper respiratory infections colchicine (1.0mg daily, 16 weeks) and placebo (31.5% vs 18.2%, respectively, P>0.05).

A randomized, open-label study by Antoniou et al. [34] reported 8 respiratory infections in patients with idiopathic pulmonary disease treated with IFN-γ compared to 2 in the colchicine group (1.0mg daily, 2 years). Pneumonia was responsible for 2 deaths in both the colchicine and INF-γ cohorts. Bessisow et al. [35] investigated whether colchicine reduced post-operative atrial fibrillation or atrial flutter after lung resection. Patients received either placebo or colchicine (1.2mg daily, 9 days). After 30 days post-operation, the rate of infections was 12% for colchicine group and 16% for control with no significant difference (adjusted HR, 1.36, 95% CI, 0.38-4.86, P>0.05). One patient developed acute respiratory distress syndrome on day 3 due to suspected pneumonia but recovered on day 11.

A retrospective, case-control study by Salt et al. [36] examined the infection risk of immunosuppressive medications in patients undergoing large joint arthroplasty. The study found that 11% of cases were prescribed colchicine compared to 9% of controls in the peri-operative period (Chi²=7.5, p<0.05). The dose and duration of colchicine was not provided.

Demidowich et al. [37] evaluated the efficacy and safety of colchicine for improving metabolic outcomes in people with metabolic syndrome. There was no significant difference in upper respiratory tract infections in the colchicine (1.0mg daily, 4 months) group compared to control (6.5% vs 12.5% patient visits, P>0.05).

Morgan et al. [38] investigated the efficacy and safety of colchicine in patients with alcoholic liver cirrhosis. Treatment with colchicine (1.2mg daily) lasted between 24 to 72 months. The primary outcome was all cause mortality but secondary outcomes included complications of liver disease. There was no significant difference in spontaneous bacterial peritonitis in the colchicine and placebo groups (6.9% vs 9.1%, respectively, P>0.05).

A retrospective cohort study by Young-Xu et al. [39] explored the relationship between colchicine use and Clostridium Difficile Infection (CDI). Data was obtained from United States Veterans Affairs system regarding patients who filled a 30-day prescription of colchicine (n=77,202). These were matched to colchicine non-users (n=308,808). Colchicine users were more likely to experience CDI (adjusted RR 1.44, 95% CI, 1.15-1.97). However, patients prescribed <1.2mg daily of colchicine exhibited a non-significant risk of CDI (adjusted RR 1.21, 95% CI, 0.76-1.94) as opposed to patients prescribed ≥1.2mg daily (adjusted RR 1.37, 95% CI, 1.09-1.73). This dose response was further supported with significant risk of CDI associated with prescriptions of colchicine for ≥90 pills or >60 days. Colchicine use was associated with increased risk of CDI recurrence (adjusted RR 1.23, 95% CI, 1.03-1.49), ICU admission or death (adjusted RR 1.44, 95% CI, 1.02-2.01).

A large randomized controlled trial by Nirdoff et al. [40] investigated the effect of colchicine in reducing the risk of cardiovascular events in patients with chronic coronary disease. A total of 5,522
patients were randomized to colchicine (n=2,762) and placebo (n=2,760). The median duration of colchicine treatment, 0.5mg daily, was 29 months. Hospitalisation rates for infections were 5.0% in the colchicine group and 5.2% in placebo (HR 0.95, 95% CI, 0.75-1.20, P>0.05). Hospitalisation rates for pneumonia were 1.7% in the colchicine group and 2.0% in placebo (HR 0.84, 95% CI, 0.75-1.20, P>0.05).

Tardif et al. [41] explored the effect of colchicine (0.5mg daily, 19.6 months) in reducing cardiovascular events after myocardial infarction. A total of 4,745 patients were enrolled and assigned to colchicine (n=2,366) or placebo (n=2,379). The median duration of treatment was 19.6 months in colchicine group and 19.5 months in placebo. Infectious adverse events were reported in 2.2% of the colchicine group compared to 1.6% in the placebo with no significant difference (P>0.05). Pneumonia was significantly more likely to occur in the colchicine group compared to placebo (0.9% vs 0.4%, respectively, P<0.05). Septic shock was reported in 0.1% of patients in both colchicine and placebo group.

A study by Zarapel et al. [42] explored whether colchicine (2.0mg daily, 24hrs before surgery and 1.0mg daily after surgery until discharge) was effective in reducing atrial fibrillation in the post-operative period of myocardial revascularization. A total of 140 patients were enrolled and assigned to receive colchicine (n=71) or control (n=69). Patients in colchicine group were more likely to experience post-operative infections compared to control group (26.8% and 8.7%, respectively, P<0.05). Details about the type of post-operative infections were not reported.

There were two studies reporting the association between colchicine usage and COVID-19 infection. A case-control study by Gendelman et al. [43] explored the association between COVID-19 and the use of hydroxychloroquine or colchicine. A sample of 14,520 patients was obtained from the Maccabi Health Services database with 1,317 positive cases of COVID-19. The rate of colchicine usage was not statistically different between those who tested positive or negative for COVID-19 (0.53% vs 0.48%, P>0.05). A web survey was conducted by Haslak et al. [44] of 404 children with autoimmune diseases. There were 376 patients on colchicine treatment and only 6 of these patients contracted COVID-19. All cases recovered completely.

Discussion

This review was based on results from interventional and observational studies with significant heterogeneity in disease states, colchicine doses and lengths of intervention. In light of these limitations, conclusions can only tentatively be drawn from the results of this systematic review.

There was minimal evidence that colchicine has a role in combating any infectious disease or its complications. In viral liver disease colchicine was primarily used to prevent liver cirrhosis or complications due to its anti-fibrotic effects [3]. Only Albillos et al. [10] and Angelico et al. [11] monitored viral load in response to colchicine treatment and found no significant change and a deleterious effect, respectively. Some viruses require the microtubule network for their replication cycle including viral entry, intracellular transport, virion assembly and exit. Colchicine has been shown to interrupt hepatitis C, flaviviruses and varicella-zoster replication in vitro [4–6] and respiratory syncytial virus (RSV) replication in mice [45]. However, other viruses such as herpes simplex (HSV) do not depend on the cytoskeleton for replication and are potentially unaffected by colchicine [46]. The impact of colchicine on viral load in viral hepatitis remains unknown. Floreani et al. [12] reported an increased antibody response in patients treated with colchicine. However, this was a pilot study with a small sample size and no significant difference between treatment and control could be drawn. There was no conclusive evidence supporting the role of colchicine in preventing complications in viral hepatitis. Arrieta et al. [9] reported a significant protective effect with delayed development of hepatocellular carcinoma. However, HBV and HCV are not believed to play a direct role in hepatocarcinogenesis and this effect was presumed to occur due to colchicine inhibiting the chronic inflammatory process and cellular proliferation exhibited in all liver disease, regardless of etiology. However, this hypothesis is not supported by a meta-analysis which found colchicine has no use in the management of alcoholic and non-alcoholic liver cirrhosis [47]. Although Lin et al. [13] reported a significant reduction in hepatitis B complications, this was defined as an acute change in ALT liver enzymes. There was no correlation to symptoms and the study found no significant difference in overall disease prognosis.

Colchicine has been shown previously to be effective as an adjunct to NSAIDs in managing acute idiopathic pericarditis and preventing recurrences [48]. These studies are based on idiopathic pericarditis with no confirmed infective origin and were subsequently excluded in this review. The study by Liebenberg et al. [20] with tuberculosis pericarditis patients found colchicine provided no significant benefit in reducing pericardial constriction. This study was a pilot study, limited to HIV positive patients and the power of the study was insufficient to detect any small differences in outcomes. The effect of colchicine in treating myocarditis is not understood. There is some evidence demonstrated by cardiac MRI that myocarditis, associated with idiopathic pericarditis is responsive to colchicine treatment [49]. The only clinical evidence in viral myocarditis was a small case series by Gultekin et al. [24] which suggested colchicine improved ventricular ejection fraction in EBV/CMV myocarditis. This study did not report on any changes in viral loads. Pre-clinical studies have suggested that colchicine treatment can in fact decrease macrophage infiltration and lead to increased viral load in both the heart and pancreas of coxsackievirus B3 infected mice leading to increased mortality [50].

The majority of evidence for the use of colchicine in managing COVID-19 was from observational studies. The case-series were generally published at the beginning of the pandemic and helped support the hypothesis that colchicine could dampen the systemic inflammatory response observed in patients with severe disease. The retrospective study by Brunetti et al. [17] was able to demonstrate significant differences in mortality and length of stay in hospital. The GRECO-19 trial was the first published randomized-controlled trial and found colchicine reduced the time to clinical deterioration but there was no difference in high-sensitivity cardiac troponin or C-reactive protein levels. It is unclear whether the clinical benefit was due to colchicine disrupting viral replication or its anti-inflammatory action. Studies involving colchicine and COVID-19 are limited by the inconsistency in standard of care in the control groups. Patients were also enrolled at varying time points after diagnosis of COVID-19 and it is unclear at what stage in the disease progression colchicine treatment is most beneficial. More results from clinical trials are needed before any conclusions can be drawn regarding the effectiveness of colchicine in managing COVID-19.

Reba et al. [21] found benefit in a colchicine-quinine therapy in treating P. falciparum using a large initial dose (5.0mg on 1st day). Colchicine may potentiate the anti-malarial effects of quinine by inhibiting merozoite invasion into red blood cells [51]. Colchicine itself is not believed to be an ideal drug against malaria since its IC50 is approximately 1000 times more in P. falciparum than mammalian cell lines creating a high risk of toxicity [52]. There was some benefit in using colchicine to treat moderate erythema nodosum leprosum reactions in lepromatous leprosy. Colchicine was used to manage the immune reaction with no evidence of impacting the causative Mycobacterium leprae infection. There was little evidence for colchicine in treating condyloma acuminate and verruca vulgaris as both studies were small case-series.

The second objective of this systematic review was to identify if colchicine resulted in increased risk of infectious adverse events. Only two of the clinical trials reported statistically significant
associations of infections with colchicine usage [41, 42]. This result aligned with the meta-analysis by Stewart et al. [7] that found no significant infection risk from pooled double-blinded randomized controlled trials. Many of the colchicine infectious events tended to be relatively uncommon and the clinical trials with small cohorts were not powered to make statistical comparisons. In the observational studies colchicine was associated with increased risks of pneumonia, CDI, UTIs, post-operative infections and H. pylori [26, 27, 30, 36, 39]. The majority of these studies did not report specific colchicine doses, length of usage and infection etiology (ie. bacterial, viral etc.). However, there appeared to be a dose response to pneumonia risk in the study by Tsai et al. [26] suggesting a possible causal relationship. The two largest clinical trials by Tardif et al. [41] and Nirdoff et al. [40] reported conflicting results. The findings by Spaetgens et al. [27] were inconsistent and there was no logical explanation why recent and past exposure conferred pneumonia risk but current colchicine use did not elevate risk. The severity of pneumonia did not appear to be related to colchicine use with these studies finding no differences in septic shock, ICU admissions or death. There appeared to be no significant association between colchicine and risk of COVID-19 infection. There was some evidence suggesting a relationship between colchicine and Clostridium difficile infection. The results by Young-Xu et al. [39] supported a dose response relationship and also found ICU admissions and death were associated with colchicine usage. A significant limitation in this study is that gastrointestinal events are the most common adverse effects associated with colchicine usage. Positive laboratory tests were required for the diagnosis of CDI but the increased prevalence of gastrointestinal symptoms due to colchicine may have decreased testing thresholds in the colchicine group. The increased risk of CDI was only accounted for patients on large colchicine doses (> 1.2mg daily) of colchicine. This result may not be generalizable to the majority of patients who are on colchicine for gout prophylaxis that requires recommended doses of only 0.6mg-1.2mg daily. The association of H. pylori with colchicine usage [30] was specific to patients with Behchet’s disease and therefore the results may not be generalizable to majority of colchicine users. A causative relationship between colchicine and H. pylori infection seems unlikely since the study by Pata et al. [30] included patients from Turkey where the vast majority of the population are infected with H. pylori in their childhood prior to any colchicine exposure. [53]

The possible susceptibility of patients to infections of presumed bacterial etiology (pneumonia, UTIs and C.difficile) could be due to multiple reasons. Colchicine selectively accumulates in neutrophils and disrupts neutrophil recruitment, adhesion and mobility. Neutrophils are the primary cells involved in the innate immune response to extracellular bacteria. Colchicine can also lead to bone marrow suppression (particularly neutropenia) from toxic oral doses [54, 55], IV administration [56] or by concurrent drug interactions. However, at clinical doses, neutropenia has also been reported in some case studies [57] and a case-control study by Todd et al. [58] found higher rates of blood dyscrasias with previous colchicine exposure. Colchicine also disrupts the NADPH oxidase complex system needed in the synthesis of superoxide anions used by neutrophils to kill bacterial pathogens. These combined effects may render the host susceptible to bacterial infections.

A significant strength of this study is the broad scope of study designs, disease states, colchicine doses and intervention lengths that were included. This provided a wide perspective of the clinical evidence regarding the associations between colchicine and infectious disease. A limitation to this study is that we only included studies that specifically reported infectious adverse events. Many randomized controlled trials have been performed using colchicine but did not report infectious events in either the colchicine or control groups. As a result, it is unclear whether this represented no infectious events or that the infectious adverse events were simply not documented.

Conclusions

This systematic review suggest there is limited scope for the use of colchicine in treating or managing infectious disease. Although colchicine has shown some anti-viral activity in vitro this has not been conclusive demonstrated clinically thus far. There is some inconclusive evidence suggesting colchicine may confer an increased risk of pneumonia and post-operative infections with studies showing conflicting results. There is promising evidence that colchicine may be a safe, effective treatment in managing COVID-19 but more results from clinical trials are needed.

Declaration of Competing Interest

TM and PR report no conflicts of interest related to this work. PR reports personal fees from Abbvie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Roche and UCB. Research grant funding from Janssen, Novartis, Pfizer and UCB. Non-financial support from BMS. All unrelated to this work.

References

[1] Slobodnick A, Shah B, Pillingier MH, Krasnokutsky S. Colchicine: old and new. Am J Med 2015;128(5):461–70.
[2] Schlesinger N, Firestein B, Brunetti L. Colchicine in COVID–19: an Old Drug, New Use. Curr Pharmcol Rep 2020;6.
[3] Leung YY, Yao Hui LL, Kraus VB. Colchicine – Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum 2015;45(3):341–50.
[4] Bost AG, Venable D, Liu L, Heinz BA. Cytokkeletal requirements for hepatitis C virus (HCV) RNA synthesis in the HCV replicon cell culture system. J Virol 2003;77(7):4401–8.
[5] Richter M, Boldescu V, Graf D, Streicher F, Dimoglo A, Bentschlagacher R, et al. Synthesis, biological evaluation, and molecular docking of combretastatin and colchicine derivatives and their HCE1-activated prodrugs as antiviral agents. ChemMedChem 2019;14(4):469–83.
[6] Cole NL, Kingley RE. Colchicine treatment in the preparation of varicella-zoster virus inocula. J Virol Methods 1992;36(1):111–8.
[7] Stewart S, Yang CK, Atkins K, Dalbeth N, Robinson PC. Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther 2020;22(1):28.
[8] Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gartzche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
[9] Rolla O, Rodriguez-Diaz JL, Rosas-Camargo V, Morales-Espinosa D, Ponce de Leon S, Kershenobich D, et al. Colchicine delays the development of hepatocellular carcinoma in patients with hepatitis virus-related liver cirrhosis. Cancer 2006;107(8):1852–9.
[10] Albillos A, Penas B, De La Revilla J, Lario M, Pastor O, Martin C, et al. Ribavirin maintenance treatment reduces portal pressure in hepatitis C virus cirrhosis: a randomized open-label trial of ribavirin versus colchicine. Hepatology 2013;58(4):SUPPL. 1:9908A–1A.
[11] Anglésco M, Corripoo M, Barlatanni A, Liuti A, Gestilde S, Hurtova M, et al. Unfavorable effects of colchicine in combination with interferon-alpha in the treatment of chronic hepatitis C. Aliment Pharmcol Therapeut 2000;14(11):1459–67.
[12] Florenco A, Collareso G, Lavello S, Di Marco M, Popovic A, Naccarato R. Preliminary results of a two-center trial with colchicine for the treatment of chronic hepatitis B. Am J Gastroenterol 2001;96(12):3452–1.
[13] Lin DY, Sheen IS, Chu CM, Liaw YF. A prospective randomized trial of colchicine in prevention of liver cirrhosis in chronic hepatitis B patients. Aliment Pharmcol Therapeut 1996;10(6):961–6.
[14] Wang YJ, Lee SD, Hsieh MC, Lin HC, Lee FY, Tsay SH, et al. A double-blind random controlled trial of colchicine in patients with hepatitis B virus-related post-necrotic cirrhosis. J Hepatol 1994;21(5):872–7.
[15] Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P, et al. Effect of colchicine vs standard care on cardiac and inflammatory bio-markers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the CRESCO–19 randomized clinical trial. JAMA Netw Open 2020;3(5):e2013136.
[16] Krissman M, Pantoni S, Colombo E, Arió P, Richini D, Miclini M, et al. Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID–19 pneumonia and acute respiratory distress syndrome. Ann Rheum Dis 2020;79(10):1286–9.
[17] Brunetti L, Diawara O, Tsai A, Firestein BL, Nahass RG, Poiani G, et al. Colchicine to weather the cytokine storm in hospitalized patients with COVID–19. J Clin Med 2020;9(9).
[18] Della-Torre E, Della-Torre F, Kusanovic M, Scotti R, Ramirez GA, Dagna L, et al. Treating COVID–19 with colchicine in community healthcare setting. Clin Immunol 2020:217.
Montealegre-Gómez G, Garavito E, Gómez-López A, Rojas-Villarraga A, Colchicine Parra-Medina R. A potential therapeutic tool against COVID-19. Experience of 5 patients. Reumatol Clin 2020.

Lienenberg J, Dold CJ, Olivier LR. A prospective investigation into the effect of colchicine on tuberculous pericarditis. Cardiovasc J Afr 2016;27(6):350–5.

Reba RC, Sheehy CW. Colchicine-Quinidine Therapy for Acute Falciparum Malaria Acquired in Vietnam. JAMA. J Am Med Assoc 1967;201(7):533–4.

Gigax JL, Robison JR. The successful treatment of intrauterine condyloma acuminata with colchicine. J Urol 1971;105(6):809–11.

Nelson LM. Experimental treatment of verruca vulgaris with locally injected colchicine. J Invest Dermatol 1951;16(3):123–4.

Gultekin N, Kucukates E. Microtubule inhibition therapy by colchicine in severe myocarditis especially caused by Epstein-Barr and cytomegalovirus co-infection during a two-year period: A novel therapeutic approach. J Pak Med Assoc 2014;64(12):1420–3.

Kar HK, Roy RG. Comparison of colchicine and aspirin in the treatment of type 2 diabetes mellitus. Osteoarthrit Cartil 2002;10(4):247.

Spaetgens B, De Vries F, Driessen JHM, Leufkens HG, Souverein PC, Boonen A, et al. Colchicine to reduce atrial fibrillation in the postoperative period of myocardial revascularization. Arquivos Brasileiros de Cardiologia 2016;107(1):4–8.

Gendelman O, Amital H, Bragazzi NL, Watad A, Chodick G. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2. Insights from a large healthcare database analysis. Autoimmun Rev 2020;19(7).

Haslak F, Yildiz M, Adreovic A, Sahin S, Koker O, Alievya O, et al. Management of childhood-onset autoimmune inflammatory diseases during the COVID-19 pandemic. Rheumatol Int 2020;40(9):1423–31.

Lu N, Yang Y, Liu H, Ding X, Ou Y, Xia J, et al. Inhibition of respiratory syncytial virus replication and suppression of BSV-induced airway inflammation in neonatal rats by colchicine. J Biotech 2019;9(11).

Matthews JD, Morgan R, Sleigher C, Frey TK. Do viruses require the cytoskeleton? Viril 2013;10:121.

Rambaldi A, Glud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochr Database Syst Rev 2005;2:Cd002148.

Alabd S, Cabello JR, Irving GJ, Qintar M, Burls A. Colchicine for pericarditis. Cochr Database Syst Rev 2014;2014(8).

Morgenstern D, Lisko J, Boniface NC, Mikolich BM, Mikolich JR. Myocarditis and colchicine: a new perspective from cardiac MRI. J Cardiovasc Magn Reson 2016;18(1):0100.

Smidle BJ, Woudstra L, Fong Hing G, Wouters D, Zeelder S, Murk J-L, et al. Colchicine aggravates coxsackievirus B3 infection in mice. Int J Cardioval 2016;216:58–65.

Bejon PA, Bannister LH, Fowler RE, Fooke SE, Webb SE, Wright A, et al. A role for microtubules in Plasmodium falciparum merozoite invasion. Parasitology 1997;114(1):1–6.

Kappes R, Rothbach P. Microtubule inhibitors as a potential treatment for malaria. F1000 Research 2017;6.

Ozden A, Bozdagi G, Ozkan M, Kose KS. Changes in the soroepidemiological pattern of Helicobacter pylori infection over the last 10 years. Turk J Gastroenterol 2004;15(2):156–8.

Harris R, Marx G, Gillett M, Kark A, Arumuthy S. Colchicine-induced bone marrow suppression: treatment with granulocyte colony-stimulating factor. Int J Rheum Dis 2004;7(2):84–8.

Polat E, Tuygun N, Akca H, Karacan CD. Evaluation of the colchicine poisoning cases in a pediatric intensive care unit: five year study. J Emerg Med 2017;54(4):499–503.

Bonnel BA, Villalba ML, Karwoski CB, Beitz J. Deaths associated with inappropriate intravenous colchicine administration. J Emerg Med 2002;22(4):385–7.

Dixon AJ, Wall GC. Probable colchicine-induced neutropenia not related to intentional overdose. Ann Pharmacother 2001;35(2):192–5.

Todd BA, Billups SJ, Delate T, Canty KE, Kaufman AB, Rawlings JE, et al. Assessment of the association between colchicine therapy and serious adverse events. Pharmacotherapy 2012;32(11):974–80.